Description: PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting ß tri-calcium phosphate granule for bone related infections applications; and BONYPID500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/maxillofacial defects, while protecting from infections. PolyPid Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.
Home Page: www.polypid.com
PYPD Technical Analysis
18 Hasivim Street
Petah Tikva,
4959376
Israel
Phone:
972 7 4719 5700
Officers
| Name | Title |
|---|---|
| Ms. Dikla Czaczkes Akselbrad | Chief Exec. Officer |
| Ms. Dalit Hazan | Exec. VP of R&D and Clinical & Regulatory Affairs |
| Mr. Ori Warshavsky | Chief Operating Officer - US |
| Mr. Jonny Missulawin | Sr. VP of Fin. |
| Evgeny Valdman | Exec. VP of Operations |
| Mr. Tal Vilnai | Gen. Counsel & Corp. Sec. |
| Ms. Rivi Lev-ari | VP of Human Resource |
| Dr. Jean-Marc Hagai Pharm.D. | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.247 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-06-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 75 |